HIND

Promotion to full Professor recognizes Dr. Sengupta’s longstanding contributions to biomedical research and translational medicine Scientific leadership and expertise in drug discovery, bioengineering and therapeutic innovation have helped shape Vyome’s research-driven approach to addressing unmet medical needs Vyome Holdings, Inc. (NASDAQ:HIND) ("Vyome"), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today congratulated its Scientific Co-Founder and Director, Dr. Shiladitya Sengupta, PhD, on his promotion to Professor of Medicine at Harvard Medical School. The academic recognition marks an important milestone in Dr. Sengupta’s

Finance executive with more than 25 years of experience brings extensive expertise in public company financial management, SEC reporting, financial operations, and governanceVyome Holdings, Inc. (NASDAQ:HIND) ("Vyome" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, today announced the appointment of senior financial executive Jerry Leonard, CPA, MBA, as Chief Financial Officer. Mr. Leonard has assumed the role from September 1st, 2026 and will oversee the Company’s financial operations, financial reporting, accounting, internal controls, and related corporate governance responsib

4 - Vyome Holdings, Inc (0001427570) (Issuer)

Chardan Capital Markets initiated coverage of Vyome Holdings with a rating of Buy and set a new price target of $3.50

3 - Vyome Holdings, Inc (0001427570) (Issuer)

8-K - Vyome Holdings, Inc (0001427570) (Filer)

8-K - Vyome Holdings, Inc (0001427570) (Filer)

Vyome Holdings, Inc. (NASDAQ:HIND, "Vyome")), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the second quarter ended June 30, 2026, and provides a corporate update. Krishna Gupta, Chairman, Vyome Holdings, said, "Vyome continues to execute with focus and discipline across its development programs while maintaining a methodical and conservative approach to capital allocation. During the quarter, we advanced our lead VT-1953 program, broadened our pipeline through the Impetis agreement and continued to strengthen our intellectual property portfolio. With a strong balance sheet and disciplined capita

10-Q - Vyome Holdings, Inc (0001427570) (Filer)

Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future partnering, licensing and regional commercialization for this $600 million marketVT-1953 for malignant fungating wounds remains Vyome's flagship program and primary capital allocation priorityVyome Holdings, Inc. (NASDAQ:HIND) ("Vyome" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, announces that the China National Intellectual Property Administration (CNIPA) has granted a patent (Chinese Pa

8-K - Vyome Holdings, Inc (0001427570) (Filer)

10-Q - Vyome Holdings, Inc (0001427570) (Filer)

8-K - Vyome Holdings, Inc (0001427570) (Filer)

VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period (P=0.0020) as scored by investigators. VT-1953 efficacy was significantly superior to the vehicle control (P= 0.0015). 70% of patients treated with VT-1953 vs 0% of patients treated with vehicle (control arm) reported an improvement in patient-reported outcome measure of impact of malodor on life by Day 14 (P= 0.0256). Patients treated with VT-1953 reported a clinically significant 2 point improvement in lesion pain by Day 14 (p= 0.0020) as scored using a 10-point VAS scale. No change seen in vehicle-treated arm. No treatment-emergent adverse effects were reported in this Phase 2 study.

Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer Research Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds ("MFW") at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 17-22, 2026, in San Diego. Venkat Nelabhotla, CEO of Vyome, stated that, "There are currently no FDA approved

DEF 14A - Vyome Holdings, Inc (0001427570) (Filer)

Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations Independent valuation consulting firm, Destum Partners, valued VT-1953 at approximately $1 billion after a successful pivotal study Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through mid 2027, taking it up to pivotal trial interim readouts Added a new CTO, SVP of Clinical Development, and Senior Medical Advisor, bringing Big P

PRE 14A - Vyome Holdings, Inc (0001427570) (Filer)

10-K - Vyome Holdings, Inc (0001427570) (Filer)

8-K - Vyome Holdings, Inc (0001427570) (Filer)

Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026 Livechain, Inc. ("Livechain") (OTCX: LICH), a subsidiary of Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), announced today that it has executed a debt purchase agreement with Remus Capital, a leading AI-focused venture capital firm, in order to acquire Sociometric Solutions, Inc, d/b/a, Humanyze ("Humanyze"), a rapidly emerging human resources data and analytics company. The transaction was structured as an all-stock transaction in which LICH issued shares of its common stock, valued at approximately $325,000, in exchange for acquiring a senior, secured convertible note issued to Remus by Humanyze. Through th

8-K - Vyome Holdings, Inc (0001427570) (Filer)

Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3M Independent third-party assessment estimates a current VT-1953 valuation of approximately $455M today and ~$1B after a successful Phase 3 study FDA interactions planned in Q2 2026 for the Phase 3 protocol based on earlier announced positive Phase 2 results Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it has filed for Orphan Drug Status for VT-1953, its lead clinical program. Key antici

Company Chose Minimal Dilution Path with No Warrants and Has Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product Vyome Holdings, Inc. ("Vyome" or the "Company") (NASDAQ:HIND) announced it has successfully funded the budget for its VT-1953 Phase 3 study, which provides the Company sufficient capital to fund the estimated costs to release Phase 3 interim results on the efficacy of its drug focused on symptoms of Malignant Fungating Wounds ("MFW"). The Company accomplished this funding need using its existing At-The-Market ("ATM") facility. Additional details on this funding are as follows: All additional funds were raised on January 27, 2026. 1,089,045 common sha

8-K - Vyome Holdings, Inc (0001427570) (Filer)